Skip to main content

Table 3 Treatment compliance

From: Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience

 

n = 169 cycles

 

No.

%

Delay 1st day

  

   1–8 days

3

1.8

   9–15 days

3

1.8

   > 15 days

1

0.6

Delay 6th day

  

   +1

11

6.5

   +2

8

4.7

   +3

5

3.0

   > +3

4

2.4

 

n = 169 cycles

 

No.

%

Dose reduction of all drugs

  

   ≤ 25%

18

10.6

   26–50%

5

3.0

   > 50%

0

0

Dose reduction of only A-T

  

   ≤ 25%

3

1.8

   26–50%

4

2.4

   > 50%

0

0

Dose reduction of only GEM

  

   ≤ 25%

2

1.2

   26–50%

7

4.1

   > 50%

0

0

  1. A, doxorubicin; T, paclitaxel; GEM, gemcitabine